Causes of death among patients randomised to treatment with salmeterol (SAL), fluticasone propionate (FP), salmeterol/fluticasone propionate combination (SFC) or placebo according to degree of adherence
| SAL (N = 1521) | FP (N = 1534) | SFC (N = 1533) | Placebo (N = 1524) | |||||
| Poor | Good | Poor | Good | Poor | Good | Poor | Good | |
| N | 294 | 1227 | 303 | 1231 | 309 | 1224 | 326 | 1198 |
| COPD, n (%) | 20 (7) | 44 (4) | 18 (6) | 49 (4) | 19 (6) | 24 (2) | 19 (6) | 41 (3) |
| COPD-related deaths, n (%) | 32 (11) | 61 (5) | 31 (10) | 75 (6) | 32 (10) | 40 (3) | 31 (10) | 60 (5) |
| Cardiovascular, n (%) | 20 (7) | 25 (2) | 27 (9) | 34 (3) | 24 (8) | 36 (3) | 25 (8) | 46 (4) |
| Pulmonary, n (%) | 27 (9) | 53 (4) | 25 (8) | 66 (5) | 29 (9) | 32 (3) | 25 (8) | 49 (4) |
| Cancer, n (%) | 11 (4) | 33 (3) | 19 (6) | 32 (3) | 10 (3) | 34 (3) | 16 (5) | 29 (2) |
| Other, n (%) | 8 (3) | 14 (1) | 7 (2) | 23 (2) | 4 (1) | 7 (<1) | 10 (3) | 13 (1) |
| Unknown, n (%) | 8 (3) | 6 (<1) | 9 (3) | 4 (<1) | 10 (3) | 7 (<1) | 11 (3) | 7 (<1) |
COPD, chronic obstructive pulmonary disease.